Data / Drug companies / Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor drugs: 22 drugs from 58 companies in the FDA NDC directory

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 182 products in this class from 58 companies, covering 22 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on March 5, 2026.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

• 58Companies
• 182Products
• 22Drugs by generic name

Drugs in the Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class

Ranked by number of companies that list the drug.

Companies with the most products in this class

Dosage forms

Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.